Takashi Fukuda

Takashi Fukuda

Auto-generated profile, based on publicly available information

Takashi Fukuda

Yamashita Thyroid Hospital

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Endocrine Journal
Verified
Journal Article
Open access
PDF file
YNYuji Nagayama
Yuji Nagayama
STSeigo Tachibana
Seigo Tachibana
TFTakashi Fukuda
Takashi Fukuda
KKKento Katsuyama
Kento Katsuyama
DTDaisuke Tatsushima
Daisuke Tatsushima
HYHiroyuki Yamashita
Hiroyuki Yamashita
No evidence-based standards exist regarding levothyroxine (LT4) replacement therapy initiation timing in patients with hyperthyroid Graves’ disease undergoing total thyroidectomy. Although LT4 replacement from the first postoperative day has been the standard of care at our hospital, its clinical validity has not been thoroughly examined. This study investigated the perioperative kinetics of thyroid hormones to assess the safety and efficacy of early LT4 initiation. Thirty patients with Graves’ disease (18 hyperthyroid and 12 euthyroid) and 12 with thyroid nodules who underwent total thyroidectomy were included. Blood samples were collected from each patient for thyroid hormone measurement on the day before surgery (D-1), 15 min after surgery (D0), at 8:00 am on days 1 (D1) and 3 (D3), and 3 weeks (W3) and 3 months (M3) after surgery. In 18 patients with hyperthyroid Graves’ disease, serum free triiodothyronine (FT3) levels significantly decreased immediately after surgery and were within the normal range by D1. Although LT4 was started on D1, FT3 levels continued to decline by D3 and remained low at W3 and M3. Serum FT4 levels followed a slower decline but remained within the normal range for M3. In patients with euthyroid Graves’ disease and those with thyroid nodules, hormone levels stayed within or around the reference range throughout the observation period. In conclusion, initiating LT4 on the day after surgery is safe and effective for maintaining thyroid function in patients with hyperthyroid Graves’ disease undergoing total thyroidectomy. These results could inform future guidelines, supporting earlier postoperative LT4 initiation.

11 September 2025 in Endocrine Research
Verified
Journal Article
Closed access
SSShinya Sato
Shinya Sato
YNYuji Nagayama
Yuji Nagayama
HSHisakazu Shindo
Hisakazu Shindo
KKKento Katsuyama
Kento Katsuyama
DTDaisuke Tatsushima
Daisuke Tatsushima
HYHiroyuki Yamashita
Hiroyuki Yamashita
Postoperative hypothyroidism, a complication of thyroid lobectomy, occurs frequently. Unique cases of post-lobectomy painless thyroiditis, a pathology not previously reported, were recently observed in our practice. In this study, we aimed to retrospectively investigate the frequency and characteristics of thyroid dysfunction after lobectomy, focusing on painless thyroiditis. A total of 193 patients with thyroid tumors, including 66 with Hashimoto's thyroiditis and 127 without Hashimoto's thyroiditis, underwent thyroid lobectomy. These patients were followed up for 49.6 (12-118) months. Thyroid dysfunction occurred in 20.7% of patients, including 31.8% (21/66) and 14.9% (19/127) of those with and without Hashimoto's thyroiditis, respectively. The types of thyroid dysfunction included thyrotoxicosis (10.0%), subclinical hypothyroidism (47.5%), and overt hypothyroidism (42.5%). Nine of 21 patients with Hashimoto's thyroiditis who developed thyroid dysfunction 1-4 months after lobectomy were diagnosed with painless thyroiditis, based on the characteristic transient hypoechogenic pattern on ultrasonography during hormonal fluctuations. Four patients developed thyrotoxicosis, one of whom subsequently become hypothyroid. Thyroid function returned to normal in all four patients. Two patients tested negative for TSH receptor antibody during the thyrotoxic period. The remaining five patients developed hypothyroidism, which was transient in three patients. Painless thyroiditis develops as post-lobectomy thyroid dysfunction in patients with Hashimoto's thyroiditis. We propose naming this condition "post-lobectomy thyroiditis," as it is believed to be triggered by surgical manipulation of the thyroid gland in individuals with underlying subclinical thyroid autoimmunity. Given its transient nature in most cases, distinguishing this condition from postoperative permanent hypothyroidism is essential.

1 January 2025 in Surgical Case Reports
Verified
Journal Article
Open access
PDF file
HYHiroyuki Yamashita
Hiroyuki Yamashita
HSHisakazu Shindo
Hisakazu Shindo
YMYusuke Mori
Yusuke Mori
DTDaisuke Tatsushima
Daisuke Tatsushima
TFTakashi Fukuda
Takashi Fukuda
SSShinya Sato
Shinya Sato
INTRODUCTION: Hypocalcemia is a common complication after total thyroidectomy, particularly in patients with Graves’ disease and high bone turnover. Preoperative vitamin D deficiency is a known risk factor for postoperative hypocalcemia; however, the effects of vitamin D supplementation remain controversial. This is the first study to document a paradoxical increase in parathyroid hormone (PTH) levels after preoperative vitamin D supplementation in a patient undergoing total thyroidectomy.CASE PRESENTATION: We report the case of a 68-year-old woman with Graves’ disease and coexisting thyroid cancer who received native vitamin D (2000 IU/day) for 4 weeks before surgery. This unexpectedly resulted in a marked increase in PTH levels and bone formation markers, suggesting the worsening of secondary hyperparathyroidism. Interestingly, fibroblast growth factor 23 levels remained unchanged despite an increase in PTH and 1,25-dihydroxyvitamin D levels. Postoperatively, she developed transient hypoparathyroidism.CONCLUSIONS: Native vitamin D supplementation may, paradoxically, worsen secondary hyperparathyroidism in some patients, highlighting the need for careful preoperative metabolic assessment and individualized management strategies.

1 January 2026 in Endocrine Journal
Verified
Journal Article
Open access
PDF file
STSeigo Tachibana
Seigo Tachibana
YNYuji Nagayama
Yuji Nagayama
TFTakashi Fukuda
Takashi Fukuda
YTYusuke Taguchi
Yusuke Taguchi
DTDaisuke Tatsushima
Daisuke Tatsushima
HYHiroyuki Yamashita
Hiroyuki Yamashita
Current guidelines recommend a 6-month contraception period following radioactive iodine therapy (RAIT) for Graves’ disease (GD), based primarily on radiation safety considerations; however, they do not account for the post-treatment surge in thyroid-stimulating antibodies (TSAb), which poses risks for fetal and neonatal GD. This retrospective study aimed to identify factors influencing TSAb trajectories and construct a predictive model for TSAb levels at 6 months after RAIT. We analyzed 82 patients who underwent RAIT, with TSAb values standardized to the upper limit of normal (ULN) to account for different assay methods. Multivariable linear regression identified the duration of antithyroid drug and potassium iodide administration, pre-RAIT TSAb levels, changes in TSAb at 3 months (3M), fractional reduction in TW at 3M, and assay method as significant predictors of TSAb levels at 6 months (adjusted R2 = 0.87). A prediction score derived from this model demonstrated excellent diagnostic performance. Receiver operating characteristic analysis yielded an area under the curve of 0.99 for predicting TSAb >3.3 ULN, corresponding to the threshold for fetal GD monitoring at approximately 20 weeks of gestation, and 0.94 for TSAb >1.0 ULN. The prediction score significantly outperformed single predictors, including baseline TSAb levels and early post-TSAb changes. In conclusion, we developed a highly accurate predictive model for TSAb levels at 6 months after RAIT by integrating early post-treatment data with pre-RAIT clinical parameters. This model enables identification of patients at risk of persistent TSAb elevation, supporting individualized counseling regarding pregnancy planning beyond the conventional 6-month contraception period.

2 June 2025 in Endocrine Research
Verified
Journal Article
Closed access
YNYuji Nagayama
Yuji Nagayama
HSHisakazu Shindo
Hisakazu Shindo
STSeigo Tachibana
Seigo Tachibana
TFTakashi Fukuda
Takashi Fukuda
KKKento Katsuyama
Kento Katsuyama
HYHiroyuki Yamashita
Hiroyuki Yamashita
Objective: This study aims to investigate the clinical and ultrasonographic features of thyroid swelling following fine-needle aspiration biopsy (FNAB), and to distinguish between symptomatic and asymptomatic forms.Methods: We retrospectively reviewed 872 patients who underwent thyroid ultrasonography before and after FNAB between January and November 2024. Patients showing new hypoechoic cracking after FNAB were identified. Clinical symptoms, degree of thyroid swelling, and outcomes were evaluated.Results: Hypoechoic cracking developed in 18 patients (2.1%), appearing immediately in 17 and at 4 hours in one. Three patients (17%) experienced symptoms such as pain or compression, all with thyroid swelling exceeding 1.8-fold the original size. The remaining 15 patients were asymptomatic, with swelling less than 1.5-fold. No clinical characteristics were significantly associated with the development of symptoms. All patients recovered spontaneously; two symptomatic cases received steroid treatment.Conclusion: Post-FNAB thyroid swelling can be classified into two entities: typical, symptomatic acute transient thyroid swelling (ATTS) and a newly proposed asymptomatic form, acute transient thyroid cracking (ATTC). Recognizing ATTC as a mild, self-limiting condition is important for avoiding unnecessary treatment and alleviating patient concern.

17 June 2026 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
YNYuji Nagayama
Yuji Nagayama
STSeigo Tachibana
Seigo Tachibana
TFTakashi Fukuda
Takashi Fukuda
DTDaisuke Tatsushima
Daisuke Tatsushima
YMYusuke Mori
Yusuke Mori
HYHiroyuki Yamashita
Hiroyuki Yamashita
Context: Athyreotic patients receiving levothyroxine (LT4) for hypothyroidism sometimes exhibit low serum free triiodothyronine (FT3) levels despite normal TSH, and experience hypothyroid-like symptoms and signs, suggesting reduced peripheral thyroid hormone action. Objective: The present study aimed to identify the most reliable biochemical marker for assessing peripheral thyroid hormone status in such patients. Methods: This was a single-center retrospective, cross-sectional study of athyreotic patients on LT4. Patients were classified according to TSH, FT3 and FT4, and selected metabolic markers potentially influenced by peripheral thyroid hormone status were compared across groups. Results: In 426 athyreotic patients taking ≥1.2 μg/kg of LT4, the majority (58%) of patients exhibited normal serum FT3 and FT4, followed by 21% with normal FT3 and elevated FT4, 18% with low FT3 and normal FT4, and 2% with low FT3 and elevated FT4. This classification corresponded well with the differences in FT3/FT4 ratios that reflect the efficiency of T4 to T3 conversion. Among 156 patients not taking anti-hyperlipidemic drugs and selected with the propensity score matching using gender as a covariate, the metabolic markers of alanine transaminase, and body mass index were significantly elevated in those with low FT3 than in those with normal FT3. Conclusion: In our cohort, lower FT3 was associated with selected metabolic markers in LT4-treated athyreotic patients, suggesting that FT3 may provide additional information on peripheral thyroid hormone status in selected patients. Prospective studies with standardized sampling and adjustment for confounding are warranted to establish FT3 as a validated marker or support FT3-guided dosing.